Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study.

Jonasson AF, Edwall L, Uvnäs-Moberg K.

Menopause Int. 2011 Dec;17(4):120-5. doi: 10.1258/mi.2011.011030. Epub 2011 Nov 25.

PMID:
22120944
2.

Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.

Al-Baghdadi O, Ewies AA.

Climacteric. 2009 Apr;12(2):91-105. doi: 10.1080/13697130802585576. Review.

PMID:
19117185
3.

Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy.

Simon JA, Maamari RV.

Climacteric. 2013 Aug;16 Suppl 1:37-43. doi: 10.3109/13697137.2013.807606. Review.

PMID:
23848490
4.

Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.

Archer DF.

J Steroid Biochem Mol Biol. 2015 Jan;145:139-43. doi: 10.1016/j.jsbmb.2014.09.003. Epub 2014 Sep 6. Review.

PMID:
25201455
5.

Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy.

Crandall C.

J Womens Health (Larchmt). 2002 Dec;11(10):857-77. Review.

PMID:
12626086
6.

Vaginal DHEA to treat menopause related atrophy: a review of the evidence.

Panjari M, Davis SR.

Maturitas. 2011 Sep;70(1):22-5. doi: 10.1016/j.maturitas.2011.06.005. Epub 2011 Jul 5. Review.

PMID:
21733647
7.
8.

Efficacy and tolerability of local estrogen therapy for urogenital atrophy.

Archer DF.

Menopause. 2010 Jan-Feb;17(1):194-203. doi: 10.1097/gme.0b013e3181a95581. Review.

PMID:
19602990
9.

Treatment of vaginal atrophy.

Domoney C.

Womens Health (Lond). 2014 Mar;10(2):191-200. doi: 10.2217/whe.14.9. Review.

PMID:
24601810
10.

Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview.

Sinha A, Ewies AA.

Climacteric. 2013 Jun;16(3):305-12. doi: 10.3109/13697137.2012.756466. Epub 2013 Jan 8. Review.

PMID:
23215675
11.

Complication of a 2-mg estradiol vaginal ring: fibrotic vaginal adhesion.

Pratts ME, Shen W.

Menopause. 2014 Nov;21(11):1254-6. doi: 10.1097/GME.0000000000000262. Review.

PMID:
24937026
12.

Emerging therapies for postmenopausal vaginal atrophy.

Pickar JH.

Maturitas. 2013 May;75(1):3-6. doi: 10.1016/j.maturitas.2013.01.020. Epub 2013 Feb 22. Review.

PMID:
23434231
13.

Postmenopausal vaginal atrophy and atrophic vaginitis.

Pandit L, Ouslander JG.

Am J Med Sci. 1997 Oct;314(4):228-31. Review.

PMID:
9332260
14.

An overview of chronic vaginal atrophy and options for symptom management.

Woods NF.

Nurs Womens Health. 2012 Dec;16(6):482-93; quiz 494. doi: 10.1111/j.1751-486X.2012.01776.x. Review.

PMID:
23253575
15.

Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?

Del Pup L, Di Francia R, Cavaliere C, Facchini G, Giorda G, De Paoli P, Berretta M.

Anticancer Drugs. 2013 Nov;24(10):989-98. doi: 10.1097/CAD.0b013e328365288e. Review.

PMID:
24080714
16.

Position of the Spanish Menopause Society regarding vaginal health care in postmenopausal women.

Sánchez-Borrego R, Manubens M, Navarro MC, Cancelo MJ, Beltrán E, Duran M, Orte T, Baquedano L, Palacios S, Mendoza N; Spanish Menopause Society.

Maturitas. 2014 Jun;78(2):146-50. doi: 10.1016/j.maturitas.2014.03.003. Epub 2014 Mar 24.

PMID:
24720907
17.

Vulvovaginal atrophy.

Mac Bride MB, Rhodes DJ, Shuster LT.

Mayo Clin Proc. 2010 Jan;85(1):87-94. doi: 10.4065/mcp.2009.0413. Review.

18.

Assessment of vaginal atrophy: a review.

Weber MA, Limpens J, Roovers JP.

Int Urogynecol J. 2015 Jan;26(1):15-28. doi: 10.1007/s00192-014-2464-0. Epub 2014 Jul 22. Review.

PMID:
25047897
Items per page

Supplemental Content

Write to the Help Desk